Security Investigation
Boston Scientific Corporation (NYSE: BSX)
58 Days left to seek lead plaintiff status.
Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 4, 2026 to file lead plaintiff applications in a securities class action lawsuit against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX).
Boston Scientific and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 4, 2026, pre-market, the Company announced its fourth quarter and full year 2025 results, disclosing disappointing U.S. Electrophysiology (“EP”) sales, and guidance for fiscal 2026 that fell well below expectations due to a combination of slower than expected market growth alongside increased competition, despite management’s previous claims of a “growing” EP business and assertions they “have a very good understanding of what competition we will face and in what time frame.”
On this news, the price of Boston Scientific’s shares fell from a closing market price of $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, a decline of about 17.6% in the span of just a single day.
If you purchased shares of Boston Scientific and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.
The case is John Rudolph Troike v. Boston Scientific Corporation, et al., Case No. 26-cv-40075.